Xenon Pharmaceuticals (XENE) Interest & Investment Income (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Interest & Investment Income data on file, last reported at $6.9 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 14.55% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $25.7 million, a 33.67% decrease from a year earlier, with the FY2025 full-year figure at $26.8 million, down 36.04% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $6.9 million, up from $5.3 million in the prior quarter.
• Over the last five years, Interest & Investment Income for XENE reached as high as $11.4 million in Q1 2024 and fell as low as $368000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $6.6 million across 5 years, with a median of $6.9 million in 2026.
• Across the five-year window, Interest & Investment Income soared 5278.95% in 2022 and sank 43.32% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $4.5 million in 2022, then soared by 94.73% to $8.7 million in 2023, then increased by 8.41% to $9.4 million in 2024, then sank by 43.32% to $5.3 million in 2025, then grew by 29.34% to $6.9 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $6.9 million in Q1 2026, $5.3 million in Q4 2025, and $6.2 million in Q3 2025.